Pharma Journalist

Disposable Solutions for Bio Manufacturing
2020-02-18 - 2020-02-20 | Leonardo Royal Hotel Berlin Alexanderplatz, Berlin, Germany, Germany
Now in it’s 12th year, the 2020 Disposable Solutions for Biomanufacturing Forum is the only global forum that focuses on the use of disposable products and single use systems in biomanufacturing. Our attendees will be guided through their journey and understand how they can run 100% disposable sites and scale their manufacturing capabilities with our newly designed program focused on implementation, systems management and future technology.

The three packed days will consist of case studies and interactive sessions to identify new technologies, determine how to approach automated systems, transition to continuous processes and learn how to implement best practice in system testing & life cycle management!
To learn more about Disposable Solutions for Bio Manufacturing and to register online, visit http://bit.ly/2Mp6lEs

Smartlab Exchange Europe
2020-02-17 - 2020-02-18 | Hotel Palace Berlin, Germany
The Smartlab Exchange is an invitation-only meeting bringing together 70 of the most senior lab leaders from across Europe, plus a number of hand-selected solution providers for two days of one-to-one business meetings, benchmarking, discussions and networking.

Key themes include:
✓ Devising a Roadmap to Success for an Agile, Adaptable, Digitised Lab
✓ Leveraging Big Data Analytics and Informatics
✓ Embedding a Culture of Collaboration and Innovation
✓ Enhancing Visibility Across Existing Systems/Processes and Integrate Emerging Technologies
✓ Implementing Methods to Safeguard Data Integrity and Uphold Regulatory Compliance
96% of our attendees would recommend our event
“I got more out of one day at Smartlab than a normal day at another conference.” – R&D IS Program Manager, Biomerieux
Below are some of the 20+ presentations and interactive sessions we have in store:

Novartis – Exploring Data Visualisation Software To Increase The Accuracy Of Your Predictions
Roche – Connecting Your Instruments For Easy Data Access And Analysis Across Your Lab
Janssen – The Lab Of The Future: Predicting How The Lab Will Develop In the Next 5 Years
UCB – Developing Your Data Capture Process For Increased Efficiency

Check out the full agenda here: http://bit.ly/2T75ps7

MarketsandMarkets Gen-Next Probiotics and Microbiome Congress
2020-02-06 - 2020-02-07 | San Diego, CA
What are the essentials being missed out on? What is the real role of probiotics strains, prebiotics and symbiotic in influencing a health? How do you standardize microbiome analysis?
Witness the major breakthroughs of microbiome, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery.

Join us at Gen-Next Probiotics and Microbiome Congress, 2020 to network with biotech, pharma, academicians and investors to exchange views and observe the most ingenious research and technologies. Understand what’s happening. Witness the amalgamation of study focused on pharmaceutical and medicinal approaches of probiotics and the nutraceutical and consumer approaches along with the role of microbiome in clinical applications and preventative medicine.
To learn more about MarketsandMarkets Gen-Next Probiotics and Microbiome Congress click here

5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
2020-02-06 - 2020-02-07
The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th – 7th February 2020 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

To learn more about 5th Annual Biomarker and Companion Diagnostics Conference click here

4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference
2020-02-06 - 2020-02-07 | San Diego, CA
Since our past editions we dedicated our focus on the latest developments and addressed various applications of CRISPR as a molecular tool, gene expression, knock-in, genomic screening, along with therapeutic developments through animal modeling. Attended by 100+ genome editing professionals and 20+ gene expert speakers, the event saw participation of big companies like Casebia Therapeutics, Genentech, BMS, Cellectis , University of Laval, University of California, Center of Advanced Genome Engineering, Georgia Tech, Stanford University, Locana, Harvard Medical School, Agility, Poseida, Vertex, Ligandal, Integrated DNA Technologies, GE Healthcare, Cellecta, Agilent, Advanced Analytical, Thermofisher, Atum, Synthego, New England Biolabs, Aldevron, Applied Stem Cell and more.

In 2020, coming with the 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference on 6th & 7th February in San Diego, we are getting ahead by discussing the commercialization and advancements of technology which will outline breakthrough advancements in pre-clinical & clinical therapeutics using genome Editing. The event will also focus on analysis of off target effects, specificity and aspects of gene and cellular therapies.
To learn more about 4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference click here

Smartlab Exchange USA
2020-02-04 - 2020-02-05 | Hilton Fort Lauderdale Marina, FL, United States
The Smartlab Exchange is an invitation-only meeting bringing together 70 of the most senior lab leaders from across the world, plus a number of hand-selected solution providers for two days of one-to-one business meetings, benchmarking, discussions and networking.

Key themes include:
✓ Devising a Roadmap to Success for an Agile, Adaptable, Digitized Lab
✓ Harnessing Lab Automation Strategies
✓ Leverage Big Data Analytics and Informatics
✓ Augmenting Existing Systems/Processes with Emerging Technologies
✓ Implementing Methods to Safeguard Data Integrity and Uphold Regulatory Compliance
96% of our attendees would recommend our event
“I got more out of one day at Smartlab than a normal day at another conference.” – R&D IS Program Manager, Biomerieux
Below are some of the 20+ presentations and interactive sessions we have in store:

Abbvie – Transforming The R&D Lab: What It Takes
IDC – Leveraging AI To Supercharge Data and Analysis Efficiencies In The Connected Lab
Pepsico – Blending Technology, Process and Digitization To Enable Smart Data-Driven Lab Transformation
Johnson & Johnson – The Digital Patient & Consumer In Healthcare

Check out the full agenda here: http://bit.ly/35z1F5m

Parallel Trade 2020
2020-02-04 - 2020-02-05 | Holiday Inn, Kensington Forum 97 Cromwell Rd, Kensington, London SW7 4DN, United Kingdom
Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
SMi presents Europe’s leading 14th annual Parallel Trade conference, taking place in London on the 4th-5th of February 2020. As the only B2B parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.
The size of the EU market in pharmaceutical distribution is around €5bn, and the UK accounts for 22.7% of this figure. The sector has an annual import value of around £1bn, while the annual export figure approximates £600m.
The 2020 event will hold a particular place of significance on shortages of medicines, current and ongoing challenges posed by Parallel Trading, potential implications of Brexit and IP exhaustion rights.
Furthermore, the FMD (Falsified Medicines Directive) will be coming into effect in February 2020. This conference will give companies affected the perfect opportunity to discuss and consider the impact that the FMD implementation will have on their practices and on the market.
The benefits of attending:
This conference is a must-attend show for anyone involved in the parallel trade industry within pharmaceuticals and life sciences. Attending the show gives you the chance to interact with and discuss common issues with leaders involved in all the areas of the parallel trade industry. Furthermore, this provides core information to further strengthen your industry knowledge and approaches.

Assessing the economic impact and dynamics of Parallel Trade
Reviewing how to overcome the challenges and hurdles in Parallel Trade
Understanding the underlying principles of the EU internal market and competition policies
Discussing the impact of Parallel trade on patient safety
What’s the impact and consequences of a no deal Brexit on testing and clinical trials?
Impact on shortages, availability, accessibility and innovation
Assessing current EU legislative instruments and changes in IP framework
An update on current illegal trade cases and the Falsified Medicines Directive

EARLY-BIRD RATES:

BOOK BY 31st OCTOBER AND SAVE £400
BOOK BY 29th NOVEMBER AND SAVE £200
BOOK BY 13th DECEMBER AND SAVE £100

Plus two pre-conference interactive workshops
Workshop A : Parallel Trade and Brexit… Where are we now?
Tushar Patel, Principal Consultant, Key Pharmaceuticals Ltd
Workshop B: Understanding IP, regulatory and competition law issues in pharmaceutical parallel trade
John Schmidt, Partner, Antitrust, Arnold & Porter Kaye Scholer
Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
LinkedIn: @SMi Pharma
Twitter: @SMiPharm #SMi #SMiParallel

Commercializing Continuous Processing in Pharma (CCP)
2020-01-28 - 2020-01-30 | The Colonnade, 120 Huntington Avenue, Boston, MA, United States
The CCP Summit 2020 is the only dedicated community for continuous manufacturing commercialization in Pharma.
Four years in the drug development world isn’t long, and the progress made in continuous processing has been an extraordinary. Thanks to the encouragement of the FDA and maturing technology; both pharma and biotech are starting to adopt continuous manufacturing (CM) in a commercial setting.
Over the last 12 months we have seen major milestones in continuous manufacturing globally – PROSPECT project in the UK, GSK’s announcement of CM facilities in Singapore, Merck has filed an NDA under CM approach, Bill & Melinda Gates Foundation granted $14.3m to Univercells to deploy CM for measles and rubella vaccine continuous manufacturing.
At the 4th Annual CCP Summit we will continue to explore scientific and technology advancements that can help eliminate bottlenecks, and more importantly, will address the quality, upfront investment and business rationale behind the ‘switch’.
This is the one and only CCP meeting bringing together small molecules and biologics experts under one roof for knowledge and experience exchange!
Join us in Boston for the 4th time on Jan 28 – 30, 2020. Find out more about the CCP Summit > https://ter.li/9slw1t

Temperature Control and Logistics
2020-01-27 - 2020-01-30 | Crowne Plaza Dusseldorf – Neuss, Dusseldorf
The Temperature Control and Logistics forum remains the industries foremost operational and hands on conference to discuss everything logistics, supply chain and temperature controlled for the Pharmaceutical Industry.

Our vision for 2020 is to ensure that we remain true to our role in the industry – building a network of world leading expert speakers and facilitators alongside the industries leading solution providers and attendees to address how we can work together to practically advance the industry past the biggest and current hurdles and challenges. We are committed to ensuring that we help every single delegate, industry partner and expert speaker to achieve their unifying goal: Transforming the industries current capabilities by optimising global logistics and supply chain processes to better serve the patient populations at the heart of the conversation.
Across four days of workshops, keynote presentations, case studies, interactive think tank discussions and networking – we will ensure that the industry leaves with the strategies, solutions and partners to overcome their most pressing operational challenges in order to make industry transformation and – patient care – possible.
To learn more about Temperature Control and Logistics visit http://bit.ly/2mRcY8I

SMi’s 9th Annual Pharmaceutical Microbiology Conference
2020-01-20 - 2020-01-21 | Copthorne Tara Hotel, London, UK, United Kingdom
SPONSORED BY
Associates of Cape Cod, bioMérieux, COPAN, METTLER TOLEDO, Microgenetics, Reading Scientific Services Limited, Veltek Associates
CHAIRED BY
James Drinkwater, Chairman, Pharmaceutical and Healthcare Science Society
Olivier Chancel, Sterility and Aseptic Practices Expert, Boehringer Ingelheim
Discovering optimised contamination control and the current regulatory landscape
Pharmaceutical Microbiology as an industry is projected to see significant advancements in the next five years. This forecast is largely attributed to rapid microbiology testing, which has accounted for $3.5 billion last year, while projected to reach nearly double at $6 billion by 2025, and an estimated CAGR of 8.3% leading up to 2025.
At the very core of pharmaceutical microbiology is the accurate and reliable detection of microorganisms that would otherwise contaminate the pharmaceutical products manufactured. This demand for more rapid methods for detection and identification will be accompanied by equally important areas such as: contamination control strategies and environmental monitoring, process automation, and discussing updates to meet regulatory requirements.
Join us at SMi’s 9th Annual Pharmaceutical Microbiology Conference to explore novel and developing technologies that tackle the most pressing challenges and push innovation in world of pharmaceutical microbiology.
Event Hashtag: #SMiPharmaMicroUK
At the 9th Annual Pharmaceutical Microbiology Conference, you will gain insight into:
FEATURED SPEAKERS INCLUDE:

Luis Meirinhos-Soares, GMP Inspector,Infarmed IP
Jim Polarine, Senior Technical Service Manager,STERIS Corporation
Tim Eaton, Sterile Manufacturing Specialist,AstraZeneca
Pratixa Patel, Senior Director,Microbiology and Stability Sciences, GSK
Ian Symonds, Pharmaceutical Consultant, SDA Pharma
Michael Song, Senior Manager,MedImmune
Maria Jose Zafra-Domene, Microbiology QC Team Leader,MeiraGTx
Ingo Spreitzer, Deputy Head Section Microbial Safety,Paul Ehrlich Institute

KEY HIGHLIGHTS INCLUDE FOR 2020

Discuss the regulatory expectations and supportive guidance on bio-contamination control and monitoring in aseptic manufacturing of sterile products fromPHSS
Gain valuable insight from key opinion leaders in a panel discussion on the impact of the Annex 1revisions on pharmaceutical microbiology
Examine the common myths and urban legends in the pharmaceutical industry related to contamination control from STERIS
Explore container closure integrity and controls strategies ensuring product sterility from AstraZeneca
Revisit the role of the Official Medicines Control Laboratories as the GMP back up from Infarmed IP

View the full agenda: www.pharma-microbiology.com/PJwl
WHO SHOULD ATTEND?
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist Drug Substance External Manufacturer, Business Development Manager – Testing, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist
EARLY BIRD-RATES

BOOK BY 30TH SEPTEMBER AND SAVE £400
BOOK BY 31ST OCTOBER AND SAVE £200
BOOK BY 29TH NOVEMBER AND SAVE £100

Disruptive Technologies in Pharma
2020-01-20 - 2020-01-21 | HOLIDAY INN KENSINGTON FORUM, 97 Cromwell Road, London, SW7 4DN, United Kingdom
The conference aims to bring together experts of emerging technologies to discover the opportunities with regards to Artificial intelligence, Machine Learning, Internet of Things, Digital therapeutics, eHealth and blockchain. The effect of these technologies on the industry will be discussed with the aim to highlight challenges related to the implementation of these new technologies and to discuss how to overcome them.

Industry case studies will reveal personal experiences and strategies to approaching digitalization, providing a benchmark for practice and improving understanding of forecasts until 2020.
Transformations require regulatory adjustments therefore, the conference will also feature insights into new regulatory guidelines and standards of practice, with special focus on the new class of drugs called digital therapeutics, to provide a complete picture of every aspect of the transformation process.
Network and learn from leading professionals such as Vice Presidents, Directors Managers and Heads of: Emerging/Disruptive Technologies, Artificial Intelligence, Machine Learning, Data Science/Analytics, Technology, External and Internal Innovation, Digital IoT and Bioinformatics
CHAIRS FOR 2020:

Karl Hess, Managing Director, OnDigitalHealth Consulting

FEATURED SPEAKERS INCLUDE:

Mark Campbell, Freelance Regulatory Expert, former NICE
Vladimir Anisimov, Principal Data Scientist, Amgen
Joseph Dalton, Global Lead Digital Health Solutions and Medical Outcomes, Novartis

For more information and to register, visit www.disruptivetech-pharma.com/pjwb
Contact Info:
T: +44 (0) 20 7827 6164
E: nhoward@smi-online.co.uk

Pre-Filled Syringes and Injectable Drug Devices 2020
2020-01-15 - 2020-01-16 | Copthorne Tara Hotel, Kensington, Scarsdale Pl, Kensington, London, W8 5SY, United Kingdom
Assessing the regulatory environment and future of PFS design and development
SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London on 15th and 16th January 2020.

As Europe’s leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.
With the rapid expansion of the PFS market, the regulatory environment is more importance than ever. This year’s programme will look at the EU MDR, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior Pre-Filled Syringes Engineers, Device Testing Managers, Heads of Late-Stage Pre-Filled Syringes Development, Head of Medical Affairs, Senior Director – Combination Products & Medical Devices, Global Regulatory Affairs, Quality Assurance Manager Combination Products , Senior Pharmaceutical Assessor and many more.
BENEFITS OF ATTENDING:

Learn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design
Debate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices
Hear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery
Assess industry case studies exploring how to overcome challenges of extractables and leachables

View the full agenda and speaker line-up online: www.pre-filled-syringes.com/pharmajwl
Plus, pre-conference workshop day will be taking place on 14th January in London:
Workshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards
Workshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller, CEO, HK Packaging Consulting GmbH
Workshop C: Extractables and Leachables: Considerations for PFS Platforms
EARLY-BIRD RATES:

BOOK BY 30TH SEPTEMBER AND SAVE £400
BOOK BY 31ST OCTOBER AND SAVE £200
BOOK BY 29TH NOVEMBER AND SAVE £100

Registrations can be made on the event website at: www.pre-filled-syringes.com/pharmajwl
Chairs for 2019:

James Mellman, Device Manager, Novartis
Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured speakers:

Abha Raveau-Violette, Device Manager, AstraZeneca
Amanda Matthews, Senior Director, Pfizer
Anil-Kumar Busimi, Strategy and Innovation, Senior Global Product Manager, SCHOTT
Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
Cedric Gysel, Healthcare Solutions Manager, Johnson & Johnson
Cinzia Rotella, Senior Materials Scientist, Sanofi
Clemens Guenther, Director Nonclinical Safety Consumer Care, Bayer
Colin Roscoe, Principal Human Factors Scientist, Teva Pharmaceuticals
Hiroki Hasegawa, Researcher, Mitsubishi Gas Chemical Company, Inc
James Mellman, Device Manager, Novartis A G
Kewei Yang, Pharmaceutical Scientist, Roche
Khaudeja Bano, Head of Medical Devices, Abbott Molecular Inc
Marion Westwood, Pharmaceutical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)
Matthew Nicolas, Investigator, GlaxoSmithKline
Nicolas Eon, Senior Global Product Manager, SCHOTT
Olaf Lebau, Design Engineer for Medical Devices and Combination Products, Boehringer Ingelheim GmbH
Raphael Nudelman, Director of Chemical and Computational Toxicology, Teva Pharmaceuticals
Remy Vomscheid, Director, Devices Development & Technologies, IPSEN Pharmsciences
Torsten Kneuss, Quality Assurance Manager Combination Products, Bayer Pharma

Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
Follow us: @SMiPharm #PFSSMi

Cell Therapy Analytical Development Summit
2019-12-10 - 2019-12-12 | Revere Hotel Boston Common 200 Stuart Street, Boston, MA, 02116, United States
The explosion in cell therapy development companies has fueled a need to develop well-characterized clinical products which has resulted in the call for robust and validated analytical assays now being louder and more important than ever before.
The inaugural Cell Therapy Analytical Development Summit brings you the leaders in CMC, analytics and process development to create standardized and automated analytical techniques and technologies for improved therapeutic characterization at scale.
Join over 100 of the world’s experts as we discuss how to navigate a murky regulatory landscape, robustly validate assays and advance the characterization of CAR-T and TCR cell therapy analytics to ensure safe, consistent and quality cell therapy products.

Get involved this December to:

Address the need to fully understand the mechanism of action of a cell therapy to develop representative potency assays
Assess methods to develop functional assays suitable for routine and timely testing to overcome operational constraints
Explore ways to develop non-destructive and non-invasive in-line analytics
Discuss current techniques being developed to standardize flow cytometry and explores ways to overcome batch effects
Highlight sources of variability in cell counting measurement such as environmental, procedural, analytical and instrumental, and techniques to minimize variability

Why do experts attend our cell therapy summits?
“Moments where we can come together with passionate individuals and companies who are focused on advancing cancer care are inspiring, and the Cell Therapy Summit is no different. We are energized by the discussions about cell therapy and its potential applications for bringing new therapies to patients in need.”
– Novartis
“This is a best in class and top summit in the cell therapy area which is an invaluable asset to both industries and academia.”
– University of Pennsylvania
Join us to ensure safe, consistent and quality cell therapy development with novel, scalable and automated analytical development assays.
To know more about Cell Therapy Analytical Development Summit click here

BioFIT 2019
2019-12-10 - 2019-12-11 | MARSEILLE CHANOT, PALAIS DES CONGRÈS ET DES EXPOSITIONS Rond Point du Prado 13008 Marseille – FRANCE
EARLY-STAGE INNOVATIONS | ACADEMIA-INDUSTRY COLLABORATIONS | TECHNOLOGY TRANSFER | SEED INVESTMENT
With the highest attending rate of TTOs, research institutes and academia together with big pharma, emerging and small biotech, diagnostics companies, pre-seed / seed / Series A investors, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.
WHY ATTEND BIOFIT?
Out of 1,000 BioFIT attendees, 1,000 deals have been generated. The breakdown in terms of nature of deals is the following:

35% of collaborative research projects
30% of licensing deals
15% of equity investment deals
20% of services deals

Estimate based on the measurement of 2015 and 2016 delegates’ outcomes

KEY FIGURES:

1,300+ delegates
800+ organisations
35+ countries represented
1,000 deals generated in 2017

INSIDE THE EVENT:

A business convention with pre-qualified one-to-one meetings
Identification of would-be CEOs
Conferences and roundtable discussions
Oral presentations of start-ups , licensing opportunities stemming from academia , service presentations
An exhibition area
Informal networking evenings

Please check out the different participants’ lists of the previous editions, as well as the list of this year’s edition >>here<<.
2018 Final programme
2019 Preliminary programme
Please feel free to widely share this document with your colleagues, network, partners…
BE PART OF THE EVENT:

Register now
Book your booth now

Website: www.biofit-event.com
Twitter: @BIOFIT_EVENT

SMi’s Inaugural Conference: Respiratory Drug Delivery 2019
2019-12-05 - 2019-12-06 | Holiday Inn Kensington Forum, 97 Cromwell Road, London, SW7 4DN, United Kingdom
SMi are pleased to announce the launch of the Respiratory Drug Delivery conference as part of the newly branded Asthma and COPD series, which will be held in London on the 5th – 6th December 2019.

With the rising prevalence of respiratory disease such as Asthma, cystic fibrosis and COPD, this group of diseases are now amongst the leading cause of death, affecting over 500 million adults and children worldwide. Lung cancer now accounts for over 50% of all respiratory disease related deaths in Europe, yet little work is being done to reduce this high mortality rate.
Opportunities for drug development has effectively resulted in the global pulmonary and respiratory drug delivery market expecting to reach 64 billion USD (6.7% CAGR) by 2025. However, the unmet medical needs of respiratory diseases sufferers remain.
Join us this year as SMi aim to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs, analysing the success of digital media devices and connective health technology in aiding the diagnosis of severe asthma and COPD. This year will also investigate the developing issues surrounding pulmonary and nasal combination product design.
Benefits of attending:

Assessing how to transform disease management through drug combinations, devices and inhaled biological treatments
Evaluating respiratory device design development and novel technologies such as nanoparticle-based drug delivery
Exploring digital connective inhalation to improve patient centricity
Reviewing the challenges around the pricing and reimbursement of respiratory drug products

View the full agenda online: www.respiratorydrugdelivery.com/pharmajwl
Early bird rates:

BOOK BY 28TH JUNE AND SAVE £300
BOOK BY 30TH SEPTEMBER AND SAVE £100

SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #SMirespiratory
LinkedIn: follow our company page – search ‘SMi Pharma’
Contact
+44 (0) 20 7827 6088
hsidhu@smi-online.co.uk

8th annual PREDiCT: Tumour Models London
2019-12-04 - 2019-12-06 | London, UK, United Kingdom
The 8th annual PREDiCT: Tumour Models London Summit will return this December with a new speaker faculty to help you benchmark your oncology model selection strategy and target validation. With the rise of immuno-oncology, model requirements, target validation and the importance of tumour micro-environment are key to clinical success. The 3-days summit will provide you with real world data from a selected model experts, including Merck, MedImmune, Takeda, Roche, AstraZeneca and more for practical insights.
To learn more about 8th annual PREDiCT: Tumour Models London and to register online, visit https://ter.li/6ge5rc

HR Life Sciences
2019-12-04 - 2019-12-05 | San Diego, CA
With the rapid rise of digital technology and shifts within the larger healthcare industry, the need to find new talent that can drive innovation has never been more critical. HR Life Sciences is specifically designed for senior HR professionals at the nation’s leading Pharmaceutical, Biotech and Medical Device companies. You’ll discover the tools, insights, innovations, and cutting-edge solutions needed to evolve your hiring strategies in a rapidly changing life science industry. Register now with code PHARMAJ20 and receive a 20% discount.

At HR Life Sciences, you’ll learn how to:

Refine your talent sourcing to meet shrinking, highly competitive talent pools
Retain and develop top talent in an ever-changing market full of mergers & acquisitions
Keep up with new and emerging employee engagement & development trends
Stay ahead of the curve with new HR technologies and tools suited to your workforce
Maintain HR’s position as a visible business partner & thought-leader

3rd Microbiome Movement – Gut-Brain Axis Summit
2019-12-03 - 2019-12-05 | Boston, MA
The 3rd Microbiome Movement – Gut-Brain Axis Summit is returning to Boston this December and will unite pioneering industry and academic researchers to establish the mechanistic pathways contributing to neurological disorder manifestation, overcome the scientific and translational challenges of working in the gut-brain setting and capitalize on this therapeutic opportunity.

This meeting provides the opportunity for you to:

Discover pioneering preclinical data implicating metabolic, immune-mediated and enteroendocrine pathways in CNS disease development
Explore translational approaches that are moving microbiome gut-brain axis science from association to causation
Learn about critical considerations for microbiome clinical trials in the neurological and mental health setting to inform symptom and treatment management
Realize the potential of microbial profiles as a biomarker for patient stratification to maximize the efficacy of already existing drugs for neurological disease
Uncover the relatively untapped commercial opportunity held by nutritional and therapeutic products for neurological and mental health

There is no question that the early market activity in the microbiome gut-brain axis space is critical in shaping its success. Join us to discover the microbiome science contributing to neurological disease and develop the next generation of microbiome-targeted products for improved neurological and mental health outcomes.
Find out more here: https://ter.li/t9gsy7

Oncolytic Virotherapy Summit 2019
2019-12-03 - 2019-12-05 | Westin Boston Waterfront, 425 Summer St, Boston, MA 02210
Now in its 5th year, the Oncolytic Virotherapy Summit is the industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications. With 3 days of in-depth cutting-edge case studies and the highest calibre of industry discussions, The OV Summit will provide the roadmap to oncolytic virotherapy success.
Hear from pharma and biotech companies of all sizes, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities. Discover the development of oncolytic viruses that engage the immune system for long-term treatment and management of cancers.
To learn more and to register online, visit: http://bit.ly/2kmZGQh

2nd Annual RNA Targeted Drug Discovery
2019-12-02 - 2019-12-04 | The Westin Copley Place, 10 Huntington Avenue, Boston, MA, 02116, United States
At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from large pharma, innovative biotech and KOLs of academia to discuss unique discovery and development challenges that must be overcome for novel RNA targeted small molecule therapeutics to achieve their seemingly limitless potential.

For the 2nd year, network with the KOLs and RNA pioneers, to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic, stimulate the discussion of successfully targeting RNA via interfering with RNA-protein interactions and seize the therapeutic opportunity in hand by re-defining the undruggable nature of RNA.
Download the Full Event Guide.
With 22 world-class speakers sharing their latest findings, join those who are re-defining the undruggable nature of RNA:

Kevin Weeks, Founder of Ribometrix; Professor of Chemistrym, University of North Carolina
Frank Slack, Co-Founder of Twentyeight-Seven Therapeutics; Professor, BIDMC
Kathryn McCabe, Sr. Director of Business Development, Eli Lilly
Martin Pettersson, Research Fellow, Pfizer
Christopher Barbieri, Senior Investigator, Bristol-Myers Squibb
Jennifer Petter, Founder & CSO, Arrakis Therapeutics
Yochi Slonim, Co-founder & CEO, Anima Biotech
Gerhard Mueller, CSO, Gotham Therapeutics
Christopher R. Trotta, VP, Biology, PTC Therapeutics

This is only some of the senior experts confirmed to present – check out the full speaker faculty and case studies here.
Once again join your RNA community at this translational and industry dedicated event focused on optimizing target validation, improving drug-like properties & accelerating the translation of selective and bioactive RNA targeted small molecule therapeutics into human clinical trials.
Check out the official event guide for full speaker details or if you’re ready to register, secure your place here.

Targeting RNA Congress
2019-11-26 - 2019-11-27 | TBC
Targeting RNA Congress

Nearly 100% of all small molecule drugs in the market are designed to target proteins. However, only 2% of the human genome actually codes for proteins, leaving the remaining noncoding DNA and in turn RNA as potentially untapped therapeutic targets.

To date, industry has focused on biological products for RNA therapeutics but the emergence of epitranscriptomics and bioinformatics tools has provided the field with a new range of drug modalities. This has led to increasing capital investment alongside collaborations within pharma and biotech to assess if RNA can be a drug target.
The Targeting RNA Congress will explore the ‘undruggable’ RNA space and showcases the latest advancements in modulation of RNA directly with small molecules and through epigenetics. The meeting will bring together academic and industry leaders who are building platforms to identify and validate targets in order to assess disease relevance approaches in the RNA world. You’ll take away actionable insights including:

Strategies to go from hit-to-lead candidates
Addressing structural biology, biochemical and biophysical attributes relevant for RNA
Approaches to overcome chemical hurdles associated with new drug discovery platforms
How mapping RNA upstream regulation can develop disease prevention products

“This meeting is an excellent opportunity to interact with one of the best collections of thought leaders and drug discovery experts in the field of epitranscriptomics, and I am looking forward to exchanging strategic insights with my colleagues aiming at unlocking an entire class of previously undruggable targets” – Dr. Gerhard Mueller, Chief Scientific Officer, Gotham Therapeutics
To learn more about Targeting RNA Congress and to register online, visit: https://go.kisacoresearch.com/l/678123/2019-09-16/ldwx

Gene Therapy Analytical Development
2019-11-19 - 2019-11-21 | Renaissance Boston Waterfront Hotel 606 Congress Street Boston, Boston, MA, 02210, United States
The inaugural Gene Therapy Analytical Development Summit will unite large pharma and innovative biotechs to develop robust analytical tools to guarantee the consistency, quality and safety of gene therapy products.

Focused specifically on addressing the unique analytical challenges posed by gene therapy vectors, this technical scientific meeting will unite the ‘boots on the ground’ scientists grappling with these challenges first-hand.
Delving into technical analytics to assess potency, capsid integrity, empty vs full capsids and viral titers of AAV and lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development.
To learn more and to register online, visit https://ter.li/z1fc6v

3rd Annual Dermatology Drug Development Summit
2019-11-19 - 2019-11-21 | Aloft Boston Seaport District, Boston, MA
The Dermatology Drug Development Summit series is a unique industry-focused forum dedicated to innovating, accelerating and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs, in the treatment of high unmet need.
The 3rd Annual Dermatology Drug Development Summit provides leading industry experts with a unique forum to debate the end-to-end challenges in dermatology drug development: from discovering new research on key disease pathways, to unveiling critical preclinical insights, discussing formulation strategies, defining the optimal clinical development plans or evaluating commercialization approaches.
Join peers and leaders in this space for an exclusive three-day meeting of comprehensive discussion, sharing of latest advances and pioneering insights, and networking opportunities.
Hear from 30+ experts including:

Sonya Abraham, Head of New Treatment Strategies, Immunology, UCB
David Rubenstein, CSO, Dermavant Sciences
Kendall Marcus, Director – Division of Dermatology & Dental Products, FDA
Michael Kuligowski, Executive Medical Director – Inflammation & Autoimmunity, Incyte Corporation
John Harris, Vice Chair of Dermatology & Director, Vitiligo Clinic & research Center, University of Massachusetts Medical School
Suma Krishnan, Founder & COO, Krystal Biotech

Across an end-to-end, comprehensive agenda, learn from case studies on:

How to enhance preclinical activities
The latest advances in translational research
How to advance topical drug development and formulation approaches
How to accelerate clinical development and what are the latest clinical results
How to tackle the evolving regulatory and commercial landscape in dermatology

Find out more here: https://ter.li/jj7wxg

1st RNA Editing Summit 2019
2019-11-19 - 2019-11-20 | Revere Hotel Boston Common, 200 Stuart St, Boston, MA, 02116, United States
Translating Emerging RNA Editing Approaches for Therapeutic Applications.
As CRISPR genome editing struggles to overcome key specificity and delivery challenges in its pursuit to realize therapeutic applications, the 1st RNA Editing Summit 2019 accelerates the translation and commercialization of RNA editing for an array of research and therapeutic applications.
As the therapeutic potential of RNA editing explodes, discover the fundamental mechanisms of RNA editing, such as recruiting endogenous ADARs with encodable guideRNAs, and learn about the novel approaches being developed to precisely and efficiently deliver intended RNA edits. With the temporary nature of RNA editing providing a huge opportunity in many areas beyond genetic diseases, uncover how to recruit endogenous editing enzymes and ultimately deliver safe and effective transcriptome edits.
Join RNA, functional genomic, cell biology and immuno-oncology experts from large pharma, biotech and academia at the 1st RNA Editing Summit 2019 in the pursuit of translating emerging RNA editing mechanisms into therapeutic reality.
To learn more about this event, and to register online, visit https://ter.li/jikni6

3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) 2019
2019-11-18 - 2019-11-20 | Revere Hotel Boston Common, 200 Stuart Street, Boston, MA, 02116, United States
AFDD is back for its third year as the only conference to bring together industry leaders, clinicians and academic experts focused on finding an effective anti-fibrotic treatment.

Over 3 days packed with compelling case studies, diverse panels and varied networking opportunities, you’ll glean insights from industry and academic leaders across fibrotic disease areas. The 2019 agenda will reflect the strides taken by the community over the past year as well as forming the future of anti-fibrotic drug development.
To learn more about this event, and to register online, visit https://afdd-summit.com/
Contact:
Phone – (+1) 617 455 4188
Email – info@hansonwade.com

Ophthalmic Drugs
2019-11-18 - 2019-11-20 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
SMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on the 18th-20th November 2019 in London, UK.

The global ophthalmic drug market size is expected to reach a value of $30 billion USD by 2023 with growing focus on alternative delivery approaches to replace intravitreal drug delivery and novel drug development being the key factors driving the market.
With this in mind, this year’s Ophthalmic Drugs conference will explore new discoveries in the treatment of ocular rare disease; innovations in gene therapy; the challenges in drug delivery through a complex barrier; patient comfort and regulatory compliance which make up core components within the Ophthalmic Drug sphere.
NEW FOR 2019:
The brand-new Focus Day on ‘Novel Drug Delivery Through a Complex Barrier’ will bring academic perspectives on the future for ocular drug delivery and notified bodies will provide a regulatory insight into this emerging field of ophthalmic drug development.
How will you benefit?
With over 15 expert presentations, the three-day agenda offers you peer-to-peer networking with Global Product Managers, Heads of Drug Development, Senior Directors of Ophthalmology, Heads of Research and Development and many more!
Network and learn from leading professionals such as:
CHAIRS FOR 2019:

Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals
Naj Sharif, Vice President, Global Ophthalmology, Santen Inc, USA

FEATURED SPEAKERS INCLUDE:

Parisa Zamiri, Global Head of Clinical Development in Ophthalmology, Novartis Pharmaceutical Inc.
Gavin Spencer, Executive Vice President and Chief Business Officer, Nicox
Aniz Girach, Chief Medical Officer, ProQR Therapeutics
Daniel Chung, Global Medical Strategy Lead- Ophthalmology, Spark Therapeutics
Michael Ehrlich, Senior Clinical Program Lead – Retinopathies, Boehringer Ingelheim
Peter Morgan-Warren, Medical Assessor, MHRA
William Dallman, Clinical Development Manager, Eyenuk

For more information and to register, visit: www.ophthalmicdrugs.com/pj
Early-Bird Rates

BOOK BY 28TH JUNE AND SAVE £300
BOOK BY 30TH SEPTEMBER AND SAVE £100

Social Media Handles
Follow us on LinkedIn ‘SMi Pharma’, Twitter @SMiPharm and use #OphthalmicDrugs
Contact Info:
T: +44 (0) 20 7827 6164
E: nhoward@smi-online.co.uk

Skin Microbiome Congress EU
2019-11-13 - 2019-11-14 | Olympia London, Hammersmith Road, Kensington, London, W14 8UX
With 2.35 billion Euros being spent on cosmetic product R&D in Europe, and Skin Microbiome being “2019’s hottest skin care trend” – a claim supported by major market researchers and beauty bibles, are you ready for the next generation of skin care?
We are bringing you the first data focused Skin Microbiome event with two concurrent tracks focused on the hard data and commercial sides of skin microbiome:

Data Track: focuses on the hard data that supports and legitimises product claims and drives increased understanding of the skin microbiome.
Commercial Track: tackles the challenges faced when building a commercially viable skin microbiome company, optimising your supply chain and executing successful marketing & communication strategies.

Discover the potential of prebiotic, probiotic and postbiotic products being developed to protect and promote a healthy microbiome and ultimately combat dermatological conditions from acne and eczema to dandruff and skin allergies. Take advantage of:

Effective Networking with 150+ innovators, start-ups, multinational companies and vendors.
Cutting Edge Research – Discover the latest advancement in therapeutic & cosmetic products containing live bacteria, bacterial extracts, or active ingredients to promote & protect the skins microbiome.
Consumer Trends – Understand how consumer trends towards natural, organic products and active beauty are shaping the evolution of products adapted to the skin microbiome.
Clinical Trials – Explore how to design an effective clinical trial & translate research into clinically & commercially viable therapeutics.
Competitive Edge – Determine how to differentiate your product line & seize this market opportunity, gaining market share with scientifically backed products.
Regulation – Understand the different paths to market & regulatory considerations necessary to launch a cosmetic or therapeutic product.

With an increasing consumer trend towards natural products, what’s more natural than harnessing the bacteria on your skin? Don’t miss your chance to understand the next generation of natural skincare products!

5th annual European Microbiome Congress
2019-11-13 - 2019-11-14 | Olympia Conference Centre, Hammersmith Rd, Hammersmith, London W14 8UX
The gut microbiota’s importance in human health and disease progression spreads far wider than just gastro-intestinal conditions. The immune, nervous and metabolic systems couple the microbiome with the rest of the body and thus play a crucial and interlinking role in extra-intestinal diseases including neurological, cancer and metabolic conditions.

For the 5th annual European Microbiome Congress, we’ve shifted the focus from gastro-intestinal to extra-intestinal as we examine the latest pre-clinical and clinical data demonstrating the gut microbiota’s role in some of the world’s most critical and costly diseases in modern society.
Join key opinion leaders from across academia and industry to examine the latest research data. This is your opportunity to find out how others plan to translate the latest understanding of the gut-microbiome into therapeutic drugs that have the power to treat cancer, metabolic, neurodegenerative and psychiatric disorders.
To learn more about 5th annual European Microbiome Congress, and to register online, visit https://microbiomecongress.com

Protein Engineering Congress EU
2019-11-12 - 2019-11-13 | Radisson Blu Hotel Frankfurt, Franklinstrasse 65, 60486, Frankfurt am Main, Germany
Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate, with competition within industries high and the need to optimise performance greater than ever.
Introducing the European Protein Engineering Congress, dedicated to uncovering the new and emerging practices, techniques and methods of protein and enzyme engineering across industries.
With pharmaceutical, flavour & fragrance, consumer goods, animal feed, and agrochemical sectors all approaching the design, build and generation of new biocatalysts and molecules not found in nature, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering.

Data Analytics for Pharma Development 2019
2019-11-12 - 2019-11-14 | Hilton Munich City, Rosenheimer Str. 15, München, 81667, Germany
Following a hugely successful event in Amsterdam last year, we’re excited to inform you that the 5th Annual Data Analytics for Pharma Development Forum will be taking place in Munich from the 13-14 November 2019. Read all about it here: Download the 2019 Agenda.

The industry needs to move past the challenge of unstructured data sets and integrating data from multiple sources to begin to work collaboratively with other departments and organisations, as well as create a real world evidence framework for our pharmaceutical development through effective data utilisation. This is why we’ve curated an industry leading program with inside expertise from the top.
So – who exactly will be there?
Scientific Director, Janssen
Principle Data Scientist, Novo Nordisk
Principal Scientist Digitalisation Lead in Large Molecule Research, Roche
Senior Director, Head, Global Real World Evidence Strategy and Analytics, Biogen
Health Informatics Director, AstraZeneca
Vice President AI and Machine Learning, BERG Health
Director, Data Science IKU in EMEA, Celgene
Global HEOR Evidence Expert Lead, Sanofi
Head Quantitative Sciences, Bill & Melinda Gates Medical Research Institute
For the first time ever we also bring you the Start-Up Afternoon, where 5+ innovative data-management start ups demonstrate their technology in lightning-round presentations.
We also know that people learn better when they’re being active, so this year we also running Certificate Course in Data Analytics to deep-dive into data strategy, advanced analytics and machine learning & AI to ensure you’re at the forefront of innovation.
We encourage the sharing of challenges and success stories through an interactive program – but most importantly, we facilitate open discussions during networking opportunities where our delegates from Big Pharma, biotech, and start-ups will be looking to you to inform their next step on how to optimise their data strategy.
With 50+ attendees and an expert speaker faculty of over 20 senior decision makers, the Data Analytics forum is Europe’s industry leading event.
Download the 2019 Agenda here to find out more about the forum
